ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTU Chad Therapeutics,

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Chad Therapeutics, AMEX:CTU AMEX Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

Chad Therapeutics Inc- (25)

19/08/2008 11:00am

Edgar (US Regulatory)


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 1-12214
CHAD Therapeutics, Inc.; American Stock Exchange LLC
 
(Exact name of Issuer as specified in its charter; and name of Exchange where security is listed and/or registered)


10200 Mason Avenue, Suite 114, Chatsworth, California 91311, (818) 882-0883
 
(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)


Common Shares, $.01 par value
 
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
     
o
  17 CFR 240.12d2-2(a)(1)
 
   
o
  17 CFR 240.12d2-(a)(2)
 
   
o
  17 CFR 240.12d2-2(a)(3)
 
   
o
  17 CFR 240.12d2-2(a)(4)
 
   
o
  Pursuant to 17 CFR240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
 
   
x
  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
 
1   Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
 
 

 


 

Pursuant to the requirements of the Securities Exchange Act of 1934, CHAD Therapeutics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
         
  CHAD Therapeutics, Inc.
 
 
Date: August 19, 2008  By:   /s/ Earl L. Yager    
    Name:   Earl L. Yager   
    Title:   Chief Executive Officer   
 

 

1 Year Chad Therapeutics Chart

1 Year Chad Therapeutics Chart

1 Month Chad Therapeutics Chart

1 Month Chad Therapeutics Chart

Your Recent History

Delayed Upgrade Clock